+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of 7TM receptor-ligand complex models using ligand-biased, semi-empirical helix-bundle repacking in torsion space: application to the agonist interaction of the human dopamine D2 receptor

Development of 7TM receptor-ligand complex models using ligand-biased, semi-empirical helix-bundle repacking in torsion space: application to the agonist interaction of the human dopamine D2 receptor

Journal of Computer-Aided Molecular Design 27(3): 277-291

Prediction of 3D structures of membrane proteins, and of G-protein coupled receptors (GPCRs) in particular, is motivated by their importance in biological systems and the difficulties associated with experimental structure determination. In the present study, a novel method for the prediction of 3D structures of the membrane-embedded region of helical membrane proteins is presented. A large pool of candidate models are produced by repacking of the helices of a homology model using Monte Carlo sampling in torsion space, followed by ranking based on their geometric and ligand-binding properties. The trajectory is directed by weak initial restraints to orient helices towards the original model to improve computation efficiency, and by a ligand to guide the receptor towards a chosen conformational state. The method was validated by construction of the β1 adrenergic receptor model in complex with (S)-cyanopindolol using bovine rhodopsin as template. In addition, models of the dopamine D2 receptor were produced with the selective and rigid agonist (R)-N-propylapomorphine ((R)-NPA) present. A second quality assessment was implemented by evaluating the results from docking of a library of 29 ligands with known activity, which further discriminated between receptor models. Agonist binding and recognition by the dopamine D2 receptor is interpreted using the 3D structure model resulting from the approach. This method has a potential for modeling of all types of helical transmembrane proteins for which a structural template with sequence homology sufficient for homology modeling is not available or is in an incorrect conformational state, but for which sufficient empirical information is accessible.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052550065

Download citation: RISBibTeXText

PMID: 23553533

DOI: 10.1007/s10822-013-9640-z

Related references

Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor. Journal of Computational Chemistry 31(4): 707-720, 2010

A Natural Mutation in Helix 5 of the Ligand Binding Domain of Glucocorticoid Receptor Enhances Receptor-Ligand Interaction. Plos one 11(10): E0164628, 2016

The Beta-Arrestin-Biased Dopamine D2 Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation. International Journal of Neuropsychopharmacology 21(12): 1102-1108, 2018

Interaction of IL-15 with the shared IL-2 receptor b and cc subunits. The IL-15/b/cc receptor-ligand complex is less stable than the IL-2/b/cc receptor-ligand complex. Journal of Immunology 156: 39-48, 1996

Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. Acs Chemical Neuroscience 8(6): 1338-1347, 2017

Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach. Journal of Computer-Aided Molecular Design 32(1): 187-198, 2018

Dopamine receptor characterization agonist requirements for binding using tritiated 6 7 di hydroxy 1 2 3 4 tetra hydro naphthalene a potential specific dopamine receptor ligand. Pharmacologist 20(3): 241, 1978

Mechanisms of ligand binding and agonist efficacy at the human D2short dopamine receptor. British Journal of Pharmacology 125(PROC Suppl. ): 73P, 1998

Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. Journal of Neural Transmission 111(2): 113-126, 2004

Sarizotan hydrochloride - Antidyskinetic drug 5-HT1A receptor agonist dopamine D-2 receptor ligand. Drugs of the Future 31(4): 314-319, 2006

Automated preparation of the dopamine D2/3 receptor agonist ligand [11C]-(+)-PHNO for human PET imaging studies. Applied Radiation and Isotopes 70(2): 380-387, 2012

Histidine 6.55 is a major determinant of ligand-biased signaling in dopamine D2L receptor. Molecular Pharmacology 79(3): 575-585, 2011

Evidence for Ligand-independent Transcriptional Activation of the Human Estrogen-related Receptor a (ERRa). Crystal Structure of ERRa Ligand Binding Domain in Complex with Peroxisome Proliferator-activated Receptor Coactivor-1a. Journal of Biological Chemistry 279(47): 330-7, 2004

A Structural Switch between Agonist and Antagonist Bound Conformations for a Ligand-Optimized Model of the Human Aryl Hydrocarbon Receptor Ligand Binding Domain. Biology 3(4): 645-669, 2014

Receptor-ligand interaction between vitellogenin receptor and vitellogenin , implications on low density lipoprotein receptor and apolipoprotein B/E The first three ligand-binding repeats of VtgR interact with the amino-terminal region of Vtg. Journal of Biological Chemistry 278(5): 2799-2806, 2003